The health innovation paradox – breakthrough medications and dedicated providers. We spend more and live fewer years than other nations.

The MAHA movement says they will restore trust in Federal health agencies that lost public support during the pandemic.

Drugs in the GLP-1 category are now being seen in a different light beyond that of weight control, and their promise is fascinating.

The economic impact of Type 2 diabetes is staggering. The time for half-measures and incremental change is long past.